Skip to main content

Table 3 Information of 4-weeks post treatment and changes in gonadal hormones

From: Metformin versus metformin plus pioglitazone on gonadal and metabolic profiles in normal-weight women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial

Gonadal hormones

PIOMET (N = 18)

MET (N = 18)

P value (Change)

4 weeks

Change from baseline

4 weeks

Change from baseline

LH (mIU/mL)

6.30 (3.99–19.84) *

-13.10 ± 15.17

11.08 (7.25–21.17)

-2.99 ± 9.47

0.0471

FSH (mIU/mL)

6.32 ± 2.78

-1.19 ± 2.26

6.59 ± 1.94

-0.46 ± 2.60

0.4648

LH/FSH

1.76 ± 1.34 *

-1.42 ± 1.81

2.16 ± 1.25

-0.22 ± 1.14

0.0498

TT (ng/mL)

0.62 (0.44–0.77)

-0.17 (-0.24 to 0.08)

0.62 (0.55-1.00) *

-0.13 (-0.25 to -0.09)

0.9708

FAI (%)

4.85 (3.95–10.81) *

-1.03 (-7.27 to -0.09)

9.82 (6.63–16.52)

-1.49 (-4.86 to -0.51)

0.0596

SHBG (nmol/L)

42.70 (33.60–66.40)

8.49 ± 15.78

26.65 (15.88–37.30)

0.44 ± 5.74

0.881

  1. PIOMET, Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets; MET, metformin; FSH, follicle-stimulating hormone; LH, luteinizing hormone; TT, total testosterone; FAI, free androgen index; SHBG sex hormone-binding globulin. Results are expressed as mean ± SD or median (25th–75th percentile). The bold font indicates statistically significant between the two groups. * P < 0.05, vs. baseline and 4-week visits